CSF biomarkers in frontotemporal lobar degeneration with known pathology.

@article{citeulike:2878399, abstract = {OBJECTIVE: To evaluate the diagnostic value of CSF biomarkers in patients with known pathology due to frontotemporal lobar degeneration (FTLD). BACKGROUND: It is important to distinguish FTLD from other neurodegenerative diseases like Alzheimer disease (AD), but this may be difficult clinically because of atypical presentations. METHODS: Patients with FTLD (n = 30) and AD (n = 19) were identified at autopsy or on the basis of genetic testing at University of Pennsylvania and Erasmus University Medical Center. CSF was obtained during a diagnostic lumbar puncture and was analyzed using assays for total tau and amyloid-beta 1-42 (A beta(42)). Patients also were assessed with a brief neuropsychological battery. RESULTS: CSF total tau level and the ratio of CSF total tau to A beta(42) (tau/A beta(42)) were significantly lower in FTLD than in AD. Receiver operating characteristic curve analyses confirmed that the CSF tau/A beta(42) ratio is sensitive and specific at discriminating between FTLD and AD, and is more successful at this than CSF total tau alone. Although some neuropsychological measures are significantly different in autopsy-proven FTLD and AD, combining these neuropsychological measures with CSF biomarkers did not improve the ability to distinguish FTLD from AD. CONCLUSIONS: The ratio of CSF tau/A beta(42) is a sensitive and specific biomarker at discriminating frontotemporal lobar degeneration from Alzheimer disease in patients with known pathology.}, address = {Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.}, author = {Bian, H. and Van Swieten, J. C. and Leight, S. and Massimo, L. and Wood, E. and Forman, M. and Moore, P. and de Koning, I. and Clark, C. M. and Rosso, S. and Trojanowski, J. and Lee, V. M. and Grossman, M. }, citeulike-article-id = {2878399}, doi = {http://dx.doi.org/10.1212/01.wnl.0000311445.21321.fc}, issn = {1526-632X}, journal = {Neurology}, keywords = {csf, frontotemporal\_dementia, neurotransmitter}, month = {May}, number = {19 Pt 2}, pages = {1827--1835}, posted-at = {2008-06-10 01:59:20}, priority = {4}, title = {CSF biomarkers in frontotemporal lobar degeneration with known pathology.}, url = {http://dx.doi.org/10.1212/01.wnl.0000311445.21321.fc}, volume = {70}, year = {2008} }

TY - JOUR ID - citeulike:2878399 L3 - citeulike-article-id:2878399 TI - CSF biomarkers in frontotemporal lobar degeneration with known pathology. JF - Neurology VL - 70 IS - 19 Pt 2 SP - 1827 EP - 1835 AD - Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. SN - 1526-632X N2 - OBJECTIVE: To evaluate the diagnostic value of CSF biomarkers in patients with known pathology due to frontotemporal lobar degeneration (FTLD). BACKGROUND: It is important to distinguish FTLD from other neurodegenerative diseases like Alzheimer disease (AD), but this may be difficult clinically because of atypical presentations. METHODS: Patients with FTLD (n = 30) and AD (n = 19) were identified at autopsy or on the basis of genetic testing at University of Pennsylvania and Erasmus University Medical Center. CSF was obtained during a diagnostic lumbar puncture and was analyzed using assays for total tau and amyloid-beta 1-42 (A beta(42)). Patients also were assessed with a brief neuropsychological battery. RESULTS: CSF total tau level and the ratio of CSF total tau to A beta(42) (tau/A beta(42)) were significantly lower in FTLD than in AD. Receiver operating characteristic curve analyses confirmed that the CSF tau/A beta(42) ratio is sensitive and specific at discriminating between FTLD and AD, and is more successful at this than CSF total tau alone. Although some neuropsychological measures are significantly different in autopsy-proven FTLD and AD, combining these neuropsychological measures with CSF biomarkers did not improve the ability to distinguish FTLD from AD. CONCLUSIONS: The ratio of CSF tau/A beta(42) is a sensitive and specific biomarker at discriminating frontotemporal lobar degeneration from Alzheimer disease in patients with known pathology. KW - csf KW - frontotemporal_dementia KW - neurotransmitter AU - Bian, H AU - Van Swieten, JC AU - Leight, S AU - Massimo, L AU - Wood, E AU - Forman, M AU - Moore, P AU - de Koning, I AU - Clark, CM AU - Rosso, S AU - Trojanowski, J AU - Lee, VM AU - Grossman, M PY - 2008/05/06/ UR - http://dx.doi.org/10.1212/01.wnl.0000311445.21321.fc ER -